7 参考文献
[1]高晓方,崔社怀. 特发性肺纤维化的抗纤维化治疗研究进展[J]. 中华结核和呼吸杂志,2004,27(6):366- 367.
[2]Sime P J,O′Reilly K M. Fibrosis of the lung and other tissues:new concepts in pathogenesis and treatment [J]. Clin Immunol,2001,99(3):308- 319.
[3]American Thoracic Society. Idiopathic fibrosis: diagnosis and treatment. International Consensus Statement. American Thoracic Society and the European Respiratory Society [J]. Am J Respir
Crit Care Med,2000,161(2 Pt 1):646- 664.
[4]Spyros A P,George K,Marilena K,et al. Relationship of BAL and lung tissue CD4 and CD8 T lymphocytes, and their ratio in idiopathic pulmonary fibrosis [J]. Chest, 2005,128 (4):2971 -
2976.
[5]Cortijo J, Cerda-Nicolas M, Serrano A, et al. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats[J]. Eur Respir J,2001,17(6):1228- 1235.
[6]Demedis M B,Convasce G C,Dekhuijzen R,et al. IFIGENIA:effects of N-acctylcuseine (NAC)on primary end points VC and dico [J]. Eur Respire J,2004,24(4):668S.
[7]Vuokko L K,Cheryl L F,Roderick J T,et al. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy [J]. Am J Res Crit Care Med,2005,172(4):417- 422.
[8]Liu H, Drew P, Cheng Y, et al. Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transpant model [J]. J Thorac Cardiovasc Surg,2005,130
(3):852- 858.
[9]Azuma A,Nukiwa T,Tsuboi E,et al. Double-blind,placebocontrolledtrial of pirfenidone in patients with idiopathic pulmonary fibrosis [J]. Am J Respir Crit Care Med,2005,171
(9):1040- 1047.
[10]Douglas W W,Ryu J H,Schroeder D R. Idiopathic pulmonary fibrosis: impact of oxygen and colchicines, prednisone, or notherapy on survival [J]. Am J Respir Crit Care Med,2000,161
(4 Pt 1):1172- 1178.
[11]Samuel C S, Unemori E N, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo [J].
Endocrinology,2004,145(9):4125- 4133.
[12]Samuel C S,Zhao C,Bond C P,et al. Relaxin-1-deficient micedevelop anage-related progression of renal fibrosis [J]. Kidney,Int,2004,65(6):2054- 2064.
[13]Edan K B,Najib T A,Michael S,et al. Interferon-1b therapy in idiopathic pulmonary fibrosis [J]. Chest,2005,128(1):203-206.
[14]Raghu G, Brown K K, Bradford W Z, et al. A placebocontrolledtrial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis [J]. N Engl J Med,2004,350(2):125- 133.
[15]Fujita M,Shannon J M,Morkawa O, et al. Overexpression of tumor necrosis factor-[alpha] diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-[beta][J].
Am J Respir Cell Mol Biol,2003,29(6):667- 676.
[16]Raghu G,Lasky U,Costable K K,et al. A randomized placebo contolled trial assessing the efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis [J]. Chest,2005,128(1):496s.
[17]Bonniaud P,Kolb M,Galt T,et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-mediated pulmonary fibrosis [J]. J Immunol,2004,173(3):2099- 2108.
[18]Mori T,Shimizu A,Masuda Y,et al. Hepatocyte growth factor stimulating endothelial cell growth and accelerating glomerular capillary repair in experimental progressive glomerulonephritis [J].
Nephron Exp Nephrol,2003,94(2):44- 54.
[19]Marchand A S, Marchal J I, Cohen M, et al. Defect of hepatocyte growth factor secretion by fibroblast s inidiopathic pulmonary fibrosis [J]. Am J Res Crit Care Med, 2003,168(10):1156- 1161.
[20]Marshall R P, McAnulty R J, Laurent G J. Angiotensin Ⅱ is mitogenic for human lung fibroblasts via activation of type the receptor [J]. Am J Respir Cirt Care Med,2000,161(7):1999-2004.
[21]夏蕾,徐启勇,叶燕青. 卡托普利对大鼠肺纤维化的影响及机制[J]. 中华结核和呼吸杂志,2004,27(1):62- 63.
[22]Otsuka M, Takahashi H, Shiratori M, et al. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin Ⅱ type 1 receptor antagonist [J]. Thorax,2004,59
(1):31- 38.
[23]Hiroshi K,Katsutoshi N,Masaru Y,et al. Anticoagulant therapy in idiopathic pulmonary fibrosis [J]. Chest, 2005,128 (3):1475- 1482.
来源:实用医学杂志 作者:刘小燕 李时悦